Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an investment of RMB 400 million (USD 55.2 million) to establish an investment unit in Shanghai. The new unit is designed to maintain ownership of its manufacturing, trade, research and development (R&D), and other business operations in mainland China. The aim is to integrate its business resources in China to support the re-upgrade of the entire industry chain.
Partnership with Lingang Special Area
The Denmark-based company also signed a deal with Shanghai’s Lingang Special Area related to cloud services. This strategic move underscores Novo Nordisk’s commitment to leveraging advanced technology to enhance its operations in China.
Historical Investments
Since the first CIIE, Novo Nordisk has invested a total of RMB 2.5 billion (USD 345.5 million) in China. These investments include the establishment of a Greater China trade and innovation center in Shanghai, a Greater China manufacturing center in Tianjin, and a research and development center in Beijing. These initiatives highlight Novo Nordisk’s long-term commitment to China and its ongoing efforts to strengthen its presence in the region.-Fineline Info & Tech
